De-Escalating Breast Cancer Therapy
- PMID: 36410355
- DOI: 10.1016/j.suc.2022.08.005
De-Escalating Breast Cancer Therapy
Abstract
The potential value of de-escalation in breast cancer therapy cannot be overstated. From reducing complications and morbidity of surgical therapy to the avoidance of chemotherapy in certain populations, the benefits of eliminating low-value therapies are significant. Further, those interventions that have minimal to no benefit may also further low-risk care cascades resulting in additional treatments or interventions without associated value, with increased financial toxicity, and resulting excess health care expenditures.
Keywords: Breast cancer therapy; Chemotherapy; De-escalation; Surgical management.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The authors have nothing to disclose.
Similar articles
-
De-Escalating the Management of In Situ and Invasive Breast Cancer.Cancers (Basel). 2022 Sep 20;14(19):4545. doi: 10.3390/cancers14194545. Cancers (Basel). 2022. PMID: 36230468 Free PMC article. Review.
-
Escalating de-escalation in breast cancer treatment.Breast Cancer Res Treat. 2022 Sep;195(2):85-90. doi: 10.1007/s10549-022-06685-2. Epub 2022 Jul 28. Breast Cancer Res Treat. 2022. PMID: 35902432
-
Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.BMC Cancer. 2022 Feb 4;22(1):141. doi: 10.1186/s12885-022-09189-w. BMC Cancer. 2022. PMID: 35120494 Free PMC article.
-
Patient perspectives on chemotherapy de-escalation in breast cancer.Cancer Med. 2021 May;10(10):3288-3298. doi: 10.1002/cam4.3891. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932097 Free PMC article.
-
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.Expert Rev Clin Pharmacol. 2019 Jan;12(1):9-16. doi: 10.1080/17512433.2019.1552134. Epub 2018 Dec 4. Expert Rev Clin Pharmacol. 2019. PMID: 30466330 Review.
Cited by
-
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.Sci Rep. 2023 Jul 24;13(1):11951. doi: 10.1038/s41598-023-38760-z. Sci Rep. 2023. PMID: 37488154 Free PMC article. Clinical Trial.
-
AI-Enhanced PET and MR Imaging for Patients with Breast Cancer.PET Clin. 2023 Oct;18(4):567-575. doi: 10.1016/j.cpet.2023.05.002. Epub 2023 Jun 17. PET Clin. 2023. PMID: 37336693 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical